Treatment of Parkinson's disease with aporphines. Possible role of growth hormone.

To avoid the main drawbacks of prolonged treatment with levodopa (involuntary movements and the "on-off" phenomenon), we administered apomorphine by mouth to 14 patients with Parkinson's disease. This treatment caused azotemia, which we circumvented by switching to N-propylnoraporpine, whose nephrotoxic dose (80 mg six times per day) was larger than its therapeutic dose (10 to 15 mg six times per day). Slowly increasing doses induced significant improvement (P less than 0.005) in all 24 patients studied, transitory mental aberrations in seven, and release of growth hormone in three patients tested. In patients previously on prolonged levodopa administration, the dyskinesia and "on-off" phenomenon were almost identical with N-propylnoraporphine, but both drawbacks were reduced or abolished in six patients by coadministration of alpha-methyldopa hydrazine plus levodopa. This coadministration seemed to abolish tachyphylaxis. We conclude that N-propylnoraporphine is very useful in the treatment of Parkinson's disease.

[1]  G. C. Cotzias,et al.  Modification of the actions of some neuroactive drugs by growth hormone. , 1976, Archives of neurology.

[2]  Sweet Rd,et al.  The "on-off" response to chronic L-DOPA treatment of Parkinsonism. , 1974, Advances in neurology.

[3]  Duvoisin Rc.  Variations in the "on-off" phenomenon. , 1974 .

[4]  Dickey Rp,et al.  Levodopa relief of bone pain from breast cancer. , 1972 .

[5]  G C Cotzias,et al.  Similarities between neurologic effects of L-dopa and of apomorphine. , 1970, The New England journal of medicine.

[6]  R. Wurtman.  Catecholamines and neurologic diseases. , 1975, The New England journal of medicine.

[7]  J. Ginos,et al.  Metabolic modification of Parkinson's disease and of chronic manganese poisoning. , 1971, Annual review of medicine.

[8]  H. Lebovitz,et al.  Stimulation of human-growth-hormone secretion by L-dopa. , 1970, The New England journal of medicine.

[9]  C. Sirtori,et al.  Metabolic responses to acute and chronic L-dopa administration in patients with parkinsonism. , 1972, The New England journal of medicine.

[10]  A. Steck,et al.  Levodopa in Parkinsonism: potentiation of central effects with a peripheral inhibitor. , 1972, The New England journal of medicine.

[11]  J. Ginos,et al.  Monoamine oxidase and cerebral uptake of dopaminergic drugs. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[12]  C. H. Mortimer,et al.  Bromocriptine treatment of acromegaly. , 1975, British medical journal.

[13]  L. Schiffer,et al.  Aromatic amino acids and modification of parkinsonism. , 1967, The New England journal of medicine.

[14]  G. C. Cotzias,et al.  Rotatory behavior induced in nigra-lesioned rats by N-propylnoraporphine, apomorphine, and levodopa. , 1975, Life sciences.

[15]  G. C. Cotzias,et al.  Protein intake and treatment of Parkinson's disease with levodopa. , 1975, The New England journal of medicine.

[16]  S. Lal,et al.  Effect of apomorphine on growth hormone, prolactin, luteinizing hormone and follicle-stimulating hormone levels in human serum. , 1973, The Journal of clinical endocrinology and metabolism.

[17]  R. Guillemin,et al.  Inhibition of growth hormone release in humans by somatostatin. , 1973, The Journal of clinical endocrinology and metabolism.

[18]  P. Leigh,et al.  Treatment of parkinsonism with bromocriptine. , 1974, Lancet.

[19]  W. H. Lawrence,et al.  Injected apomorphine and orally administered levodopa in Parkinsonism. , 1972, Archives of neurology.

[20]  C. Markham.  The choreoathetoid movement disorder induced by levodopa , 1971, Clinical pharmacology and therapeutics.

[21]  D. Schalch,et al.  A Sensitive Double Antibody Immunoassay for Human Growth Hormone in Plasma , 1964, Nature.

[22]  F. C. Brown,et al.  Defective release of growth hormone in parkinsonism improved by levodopa. , 1973, The New England journal of medicine.

[23]  V. G. Vernier,et al.  Amantadine-Dopamine Interaction: Possible Mode of Action in Parkinsonism , 1970, Science.

[24]  W. Ganong,et al.  Effect of synthetic somatotropin release inhibiting factor on the increase in plasma growth hormone elicited by L-dopa in the dog. , 1974, Endocrinology.